Dydrogesterone (Duphaston®) and its 20-dihydro-derivative as selective estrogen enzyme modulators in human breast cancer cell lines. Effect on sulfatase and on 17β-hydroxysteroid dehydrogenase (17β-HSD) activity

Anticancer Research

Volumn 24, Issue 3 A, 2004, Pages 1433-1438

  Chetrite, Gérard Samuel ^a   Thole, Hubert H ^b   Philippe, Jean Claude ^a   Pasqualini, Jorge Raul ^a  

^a Institut de Puericulture   (France)

^b Solvay Pharmaceuticals GmbH   (Germany)

Author keywords

17 hydroxysteroid dehydrogenase; Breast cancer cells; Dydrogesterone; Progestins; Sulfatase

Indexed keywords

20 DIHYDRODYDROGESTERONE; AROMATASE; DRUG METABOLITE; DYDROGESTERONE; ESTRADIOL; ESTROGEN; ESTRONE; ESTRONE SULFATE; PROGESTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SULFATASE; SULFATE; SULFOTRANSFERASE; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG; 3 (OR 17) BETA HYDROXYSTEROID DEHYDROGENASE; 3 (OR 17)-BETA-HYDROXYSTEROID DEHYDROGENASE; DRUG DERIVATIVE; ENZYME INHIBITOR; ESTRONE SULFATASE; HYDROXYSTEROID DEHYDROGENASE;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN MCF 7; CELL STRAIN T 47D; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; ESTROGEN METABOLISM; ESTROGEN SYNTHESIS; HORMONE DETERMINATION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; THIN LAYER CHROMATOGRAPHY; BIOSYNTHESIS; BREAST TUMOR; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; NEOPLASM; TUMOR CELL LINE;

17-HYDROXYSTEROID DEHYDROGENASES; BREAST NEOPLASMS; CELL LINE, TUMOR; DYDROGESTERONE; ENZYME INHIBITORS; ESTRADIOL; ESTRONE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; SULFATASES;

EID: 3242707858     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Abul-Hajj YJ, Iverson R and Kiang DT: Aromatization of androgens by human breast cancer. Steroids 33: 205-222, 1978.
2. Perel E, Wilkins D and Killinger DW: The conversion of androstenedione to estrone, estradiol, and testosterone in breast tissue. J Steroid Biochem 13: 89-94, 1980.
3. Vignon F, Terqui M, Westley B, Derocq D and Rochefort H: Effects of plasma estrogen sulfates in mammary cancer cells. Endocrinology 106: 1079-1086, 1980.
4. Pasqualini JR, Gelly C and Lecerf F: Estrogen sulfates: biological and ultrastructural responses and metabolism in MCF-7 human breast cancer cells. Breast Cancer Res Treat 8: 233-240, 1986.
5. MacIndoe JR, with the technical assistance of Woods G, Jeffries L and Hinkhouse M: The hydrolysis of estrone sulfate and dehydroepiandrosterone sulfate by MCF-7 human breast cancer cells. Endocrinology 123: 1281-1287, 1988.
6. Abul-Hajj YJ, Iverson R and Kiang DT: Estradiol 17β-hydroxysteroid dehydrogenase and estradiol binding in human mammary tumors. Steroids 33: 477-484, 1979.
7. Bonney RC, Reed MJ, Davidson K, Beranek PA and James VHT: The relationship between 17β-hydroxysteroid dehydrogenase activity and oestrogen concentrations in human breast tumours and in normal breast tissue. Clin Endocr 19: 727-739, 1983.
8. 3H-œstradiol by normal breast and breast tumour tissues in post-menopausal women. Int J Cancer 38: 193-196, 1986.
9. Pasqualini JR, Chetrite G, Blacker C, Feinstein M-C, Delalonde L, Talbi M and Maloche C: Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer. J Clin Endocr Metab 81: 1460-1464, 1996.
10. Chetrite G, Cortes-Prieto J, Philippe J-C, Wright F and Pasqualini JR: Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J Steroid Biochem Molec Biol 72: 23-27, 2000.
11. Santner SJ, Feil PD and Santen RJ: In situ estrogen production via the estrone sulfatase pathway in breast tumors: Relative importance versus the aromatase pathway. J Clin Endocr Metab 59: 29-33, 1984.
12. Dao TL and Libby PR: Conjugation of steroid hormones by normal and neoplastic tissues. J Clin Endocr 28: 1431-1439, 1968.
13. Tseng L, Mazella J, Lee LY and Stone ML: Estrogen sulfatase and estrogen sulfotransferase in human primary mammary carcinoma. J Steroid Biochem 19: 1413-1417, 1983.
14. Pasqualini JR: Steroid sulphotransferase activity in human hormone-independent MDA-MB-468 mammary cancer cells. Eur J Cancer 28A: 758-762, 1992.
15. Burton K: A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J 62: 315-323, 1956.
16. Brodie AMH, Wing LY, Dowsett M and Coombes RC: Aromatase inhibitors and treatment of breast cancer. J Steroid Biochem 24: 91-97, 1986.
17. de Jong PC, van de Ven J, Nortier HWR, Maitimu-Smeele I, Donker TH, Thijssen JHH, Slee PHTJ and Blankenstein RA: Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor Vorozole. Cancer Res 57: 2109-2111, 1997.
18. Poutanen M, Moncharmont B and Vihko R: 17β-Hydroxysteroid dehydrogenase gene expression in human breast cancer cells: regulation of expression by a progestin. Cancer Res 52: 290-294, 1992.
19. 3H-œstradiol by normal breast and breast tumour tissues in post-menopausal women. Int J Cancer 38: 193-196, 1986.
20. Couture P, Thériault C, Simard J and Labrie F: Androgen receptor-mediated stimulation of 17β-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. Endocrinology 132: 179-185, 1993.
21. Nguyen B-L, Chetrite G and Pasqualini JR: Transformation of estrone and estradiol in hormone-dependent and hormone-independent human breast cancer cells. Effects of the antiestrogen ICI 164,384, danazol, and promegestone (R-5020). Breast Cancer Res Treat 34: 139-146, 1995.
22. Peltoketo H, Isomaa VV, Poutanen MH and Vihko R: Expression and regulation of 17β-hydroxsteroid dehydrogenase type 1. J Endocr 150: S21-S30, 1996.